KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements
Yan Zi Au(Wellcome Sanger Institute), Kosuke Yusa(Kyoto University), Malgorzata Gozdecka(Wellcome Sanger Institute), Swee Hoe Ong(Wellcome Sanger Institute), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Jason Yu(La Roche College), Konstantinos Tzelepis(Wellcome/MRC Cambridge Stem Cell Institute), Demetrios Aspris(Wellcome Sanger Institute), Muxin Gu(Wellcome/MRC Cambridge Stem Cell Institute), Étienne De Braekeleer(Wellcome Sanger Institute), Yusuke Tarumoto(Kyoto University), Xi Chen(University of Southern California), Jonathan Cooper(Wellcome Sanger Institute)
Cited by 52
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k